Sector News

MedTrace Pharma announces first subject scanned in the company’s RAPID-WATER-FLOW Phase 3 clinical trial

June 11, 2022
Life sciences

MedTrace Pharma A/S, a pharma and device company and an innovator in PET diagnostic imaging, announced today that it has scanned the first subject in its RAPID-WATER-FLOW Phase 3 clinical trial.

The global trial enrolls adults with suspected Coronary Artery Disease (CAD) and seeks to evaluate the use of 15O-water PET in diagnosing CAD.

The first subject scan took place at Aarhus University Hospital (AUH) in Denmark just two months after MedTrace received FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the trial.

Marcelo Di Carli, MD, Professor of Radiology and Medicine, at Brigham and Women’s Hospital and Harvard Medical School, is leading the trial as Principal Investigator.

– I am thrilled by the recruitment of the first subjects into the RAPID-WATER-FLOW study. This is a significant milestone for this exciting and important study and the first step towards bringing 15O-water as a clinical myocardial perfusion agent in the United States. The practical real-time production of 15O-water with MedTrace’s novel technology promises to revolutionize the practice of cardiac PET imaging by improving patient access to the most accurate approach to the non-invasive diagnosis of coronary artery disease, says Marcelo DiCarli.

15O-water at the point of care
MedTrace’s technology automatically produces and administers 15O-water to patients at the point of care. The automated software solution also provided by MedTrace (aQuant, in development) makes available a fully quantitative as well as visual 15O-water image analysis, including quantification of blood flow and segmental perfusion data, aiming to allow healthcare professionals to diagnose patients accurately and quickly.

The innovative solution allows for absolute blood flow imaging and quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for quantitative myocardial perfusion imaging.

Hospitals produce the radioactivity themselves on demand and are not dependent on third-party suppliers for radiopharmaceuticals.

Lars Christian Gormsen, Consultant, Professor at the Department of Nuclear Medicine & PET Center at AUH is the PI for the trial at AUH and is happy to be the first site to enroll a subject in this milestone study.

– Thanks to the excellent work by our colleagues at the Department of Cardiology and the staff at the department of Nuclear Medicine, the recruitment and subsequent examination of the first patient in the project progressed as planned. We are confident that this will also be the case in the remaining part of the project, says Lars Christian Gormsen.

At MedTrace the first subject enrolled is celebrated throughout the organization.

– I am beyond impressed with the dedication from the MedTrace clinical team and from our partners at AUH. They made it possible to reach this significant milestone in less than two months after we received the green light from the FDA. It shows that our company is moving at an incredible pace which is made possible by the talented and passionate people onboard, says Martin Stenfeldt, CEO of MedTrace.

The company is currently exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology. MedTrace’s clinical department will be growing significantly by the end of the year.

For more information on the 15O-water RAPID-WATER-FLOW clinical trial, visit: Radiolabeled Perfusion to Identify Coronary Artery Disease Using Water To Evaluate Responses of Myocardial Flow – Full-Text View –

About the RAPID-WATER-FLOW Trials

The trial is a Phase 3, prospective, open-label, multicenter study of 15O-H2O injection for PET imaging of subjects with suspected CAD. 182 evaluable participants with suspected CAD will be included in the study at an estimated 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled in total to account for an estimated 15% drop-out rate. All participants will receive two doses of 15O-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).

By MedTrace, Press Release


comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach